Two years ago, Phibro Animal Health was earning six cents a share on a billion dollars of sales. That is not a typo. The company that had quietly supplied feed additives and specialty ingredients to livestock producers for decades had watched its net margin collapse to a sliver, even as revenue kept growing. Now the same business is posting earnings per share above two dollars on sales of one and a half billion. Those two readings belong to the same company, and the gap between them is the story.
The quick read
The 10-K filed August 26, 2026 shows Phibro’s net margin recovering from near-zero to 6.6% in fiscal year 2026, its best in at least five years. The stock has pulled back meaningfully even as the underlying earnings number has multiplied. Our data puts the current price-to-earnings multiple at 32.7 against a decade median of 16.5. The math has improved sharply; the mood has not caught up, but the multiple already prices in a great deal of continued recovery. That tension is what the filing forces a reader to sit with.
What the filing actually says
Phibro’s business is not glamorous. The company makes the additives that go into animal feed, the specialty nutrients that keep livestock healthy at scale, and the ingredients that sit between a farm and a finished product. It is infrastructure, not innovation, which is precisely why the margin collapse of fiscal 2024 was so jarring. Infrastructure businesses are supposed to be steady. Something broke, and the fiscal 2026 annual report is the first full-year document showing the repair.
Total net sales reached $1.5 billion for the year ended June 30, 2026, up 17% from the prior year. More telling is what happened below the revenue line. Net income came in at $99.7 million, a jump of more than half again what the company earned the year before. To feel the scale of that: Phibro more than doubled its bottom-line profit while adding roughly one dollar in six to its top line. Adjusted EBITDA, a measure of operating cash generation before interest, taxes, and accounting charges, rose sharply from the prior year’s level.
The two-year hole and how it was filled
To understand what compounded here, it helps to go back to fiscal 2024. That year, the annual filing recorded earnings per share of just $0.06 on revenue of roughly a billion dollars. A business earning six cents per share on that scale of sales is, in practical terms, covering its costs and little else. Shareholders were being asked to hold a company with the revenue profile of a mid-sized industrial and the profit profile of a startup burning cash.
The recovery did not happen in one move. The fiscal 2025 filing showed revenue jumping sharply as the company absorbed what appears to have been a significant acquisition or volume expansion, with earnings per share recovering to $1.19. Fiscal 2026 then added the margin discipline on top of the volume: revenue grew again, but net income grew faster, pushing the net margin from 3.7% to 6.6%. That sequence, volume first then margin, is the classic sign of a fixed-cost business finding its operating leverage. When sales grow faster than costs, each additional dollar of revenue drops more profit to the bottom line than the last one did.
Where the competitive picture sits
Phibro operates in a corner of animal health that its larger rivals largely ignore. Elanco reported solid organic revenue growth in Q2 2026, driven by pharmaceutical products like Zenrelia and Credelio, drugs prescribed by veterinarians for companion animals. Zoetis, the sector’s largest player, saw U.S. companion animal revenue fall meaningfully in the same quarter as generic competition arrived. Neither company competes directly with Phibro’s feed additive and specialty ingredient model, which sells into livestock production rather than veterinary clinics. That distinction matters because Phibro’s revenue is less exposed to the companion animal market softness that pressured Zoetis, and less dependent on blockbuster drug cycles that define Elanco’s story.
What the multiple is saying
The math, meaning what the filed fundamentals show, has clearly improved. The mood, meaning what the market currently pays for each dollar of those earnings, is the complication. Our data puts Phibro’s price-to-earnings ratio at 32.7 against a decade median of 16.5. A multiple is simply the price tag per dollar of annual profit: at the current level, a buyer is paying roughly twice what history suggests is normal for each dollar Phibro earns in a year. The stock is priced at nearly twice its historical norm, even after falling sharply from its 52-week high. That combination, a recovering business and an elevated multiple, is not a contradiction. It means the market has already credited Phibro for the turnaround and is pricing in continued improvement. Whether the improvement continues is exactly what the filing cannot answer.
Reading the numbers
- $1.5 billion in net sales, fiscal year ended June 30, 2026. What it is: total revenue for the year, from the 10-K filed August 26, 2026. What it means here: Phibro has grown from a $833 million business in fiscal 2021 to a $1.5 billion one in five years, a cumulative gain of about 82%. In everyday terms: a supplier that once filled one truck now fills roughly two trucks of the same goods for the same customers.
- Net income of $99.7 million, up $51.5 million year over year. What it is: the profit left after every cost, interest payment, and tax bill. What it means here: the company added more than half again as much profit in one year as it earned the year before. In everyday terms: a shop that cleared $48 in profit on $100 of sales last year cleared $100 this year on $117 of sales, because its fixed costs did not grow as fast as its revenue.
- Adjusted EBITDA of $255 million. What it is: operating cash generation before interest, taxes, depreciation, and amortization, a rough measure of how much cash the core business produces before financing and accounting choices. What it means here: the gap between $255 million in EBITDA and $99.7 million in net income reflects interest costs and taxes, not operational weakness. In everyday terms: a landlord collecting $2,550 in rent but netting $997 after mortgage interest and property taxes, the building itself is productive even if the financing takes a large share.
- P/E of 32.7 versus decade median of 16.5 (our data). What it is: the current market price divided by the most recent annual earnings per share, compared to the midpoint of that ratio over the past ten years. What it means here: the stock costs roughly twice its historical norm per dollar of profit. In everyday terms: a coffee shop that historically sold for ten times its annual profit is now listed at twenty times, because buyers expect profits to keep rising. If they do not, the price has further to fall.
Sources
- Phibro 10-K, fiscal year ended June 30, 2026 (SEC EDGAR)
- Phibro 10-K, fiscal year ended June 30, 2025 (SEC EDGAR)
- Phibro 10-K, fiscal year ended June 30, 2024 (SEC EDGAR)
- Elanco Animal Health Q2 2026 press release
- Phibro Q4 and fiscal year 2026 earnings press release
